Journal of Generic Medicines - Figure 2 for article: Patent expiries in the US statin market: Generics to slash market size by 80 per cent over the next ten years

FROM:

Patent expiries in the US statin market: Generics to slash market size by 80 per cent over the next ten years

Duncan Emerton

Figure 2.

Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Between 2006 and 2011, the value of the branded US statin monotherapy market is expected to fall by US$8bn (50 per cent) due to generic incursion on branded statin revenues
Source: Datamonitor forecasts; patent data obtained from Dolphin, Q2 2006, © Thomson Scientific; FDA Orange Book; MedTRACK, © Datamonitor plc; all accessed during July 2006

Previous figureFigure and tables index

BACK TO ARTICLE

FIGURE 2

Patent expiries in the US statin market: Generics to slash market size by 80 per cent over the next ten years

Figure 2.